|
Contents |
|
|
|
|
|
|
Astrocytic
Tumors
|
|
|
|
|
Alba A. Brandes, Linda Nicolardi,
Alicia Tosoni, Marina Gardiman, Paolo Iuzzolino,
Claudio Ghimenton, Michele Reni, Antonino
Rotilio, Guido Sotti and Mario Ermani
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma
Neuro-oncol 2006 8(3):253-260; DOI:10.1215/15228517-2006-005. First published on
May 24, 2006
Abstract
|
Full
Text | 
Reprint
|
|
|
Chamberlain
MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ.
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory
anaplastic astrocytoma
Cancer. 2008 May 1;112(9):2038-45.
Epub 2008 Mar 24
Abstract |
Links | BL 7:12
|
|
|
Advanced
Cancer
|
|
|
|
S
Ablett, V Batra, M Dugan, EJ Estlin, R Gowing, J Kohler, L Lashford, I
Lewis, H MacDowell, B Moreland, AD Pearson, CR Pinkerton, L Price, P
Reidenberg, P Statkevich, D Walker
Phase I study of temozolomide in pediatric
patients with advanced cancer
ASCO Proceedings, 1996 Annual Meeting, Abstract
|
|
V
Batra, M Dugan, SL Gerson, J Haaga, L Liu, S Majka, P Reidenberg, J
Schupp, TP Spiro, P Statkevich, JK Willson
Rapid
depletion of O6-alkylguanine DNA alkyltransferase with twice daily oral
temozolomide (SCH 52365) in patients with advanced cancer
ASCO
Proceedings, 1996 Annual Meeting,
Abstract
|
|
D
Cutler, Louis Denis, R Drengler, S Eckhardt, Jose Figueroa, C Geyer, L Reyderman,
Eric Rowinsky, A Tolcher, Daniel Von Hoff
Protracted
Cyclic Administration of Temozolomide Is Feasible; a Phase I, Pharmacokinetic
and Pharmacodynamic Study
ASCO Proccedings, 2000
Annual Meeting, Abstract No. 868
|
|
D
Cutler, Louis Denis, R Drengler, S Eckhardt, Jose Figueroa, C Geyer, L
Reyderman, Eric Rowinsky, A Tolcher, Daniel Von Hoff
Protracted Daily Administration of Temozolomide
Is Feasible: A Phase I and Pharmacokinetic - Pharmacodynamic Study
ASCO Proccedings, 2000
Annual Meeting, Abstract No. 786
|
|
Dhodapkar
M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ.
Phase
I trial of temozolomide (NSC 362856) in patients with advanced cancer
Clin Cancer Res 1997 Jul;3(7):1093-100
|
|
Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A,
Kohler J, Lewis IJ, Morland B, Pinkerton CR, Stevens MC, Mott M, Stevens
R, Newell DR, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P,
Statkevich P, Marco A, Batra V, Dugan M, Pearson AD.
Phase
I study of temozolomide in paediatric patients with advanced cancer.
United Kingdom Children's Cancer Study Group
Br J Cancer 1998
Sep;78(5):652-61
|
|
Birgit
Geoerger, Gilles Vassal, Francois Doz, Marie A Raquin, Didier Frappaz,
Pascal Chastagner, Herve Rubie, Jean-Claude Gentet, John O'Quigley, Kamal
Djazouli, Geoffrey P Margison, Francois Pein
Dose-finding
study and O6-alkyltransferase depletion of cisplatin combined with
temozolomide in pediatric solid malignancies
ASCO Proceedings, 2002
Annual Meeting, Abstract No. 424
|
|
Rakesh
Goel, Stanley Gertler, David J Stewart, Scott Laurie, Glenwood Goss,
Neil Reaume, Joanne Roach, Deborah Bedard, Angela Rodgers, David Cutler
Phase I study of temozolomide in conjunction with
gemcitabine
ASCO Proceedings, 2002 Annual Meeting, Abstract No. 2162
|
|
SF
Jones, FA Greco, JD Hainsworth, VG Gian, FT Miranda, JF Patton, NT
Willcutt, MN Baker, HA Burris III
A Phase I Trial of Chronic Oral Fixed Dose
Temozolomide
ASCO Proceedings, 2001
Annual Meeting, Abstract No. 466
|
|
Newlands
ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS,
Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al.
Phase I trial of temozolomide (CCRG 81045:
M&B 39831: NSC 362856)
Br J Cancer 1992 Feb;65(2):287-91
|
|
|
Brain Tumors
|
|
|
|
R.
Goel, S. Gertler, D. J. Stewart, S. Laurie, G. Goss, N. Reaume, C.
Cripps, D. Bedard, A. Rodgers, D. Cutler
Phase I study of temozolomide in conjunction with
gemcitabine
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2127
|
|
Darren
Hargrave, Diana Stempak, Max Coppes, Albert Moghrabi, Janet Gammon,
Angela Rodgers, Eric Bouffet, Gideon Koren, Jean Marie Leclerc, Sylvain
Baruchel
Pilot study of oral continuous administration
of low dose temozolomide in pediatric brain tumors
ASCO Proceedings, 2002
Annual Meeting, Abstract No. 1590
|
|
|
Jakacki RI, Hamilton M, Gilbertson RJ, Blaney
SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC
Pediatric phase I and pharmacokinetic study of erlotinib followed by the
combination of erlotinib and temozolomide: a Children's Oncology Group Phase
I Consortium Study
J
Clin Oncol. 2008 Oct 20;26(30):4921-7.
Epub 2008 Sep 15
Abstract |
Links | 
Issue
|
|
B.
E. Lally, J. Lacy, J. M. Piepmeier, J. M. Baehring, D. B. Fischer, J.
P. S. Knisely
Survival analysis for patients with primary brain
tumors treated with temozolomide
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract
No. 453
|
|
|
Nicholson HS, Kretschmar CS, Krailo M, Bernstein
M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C,
Sato J, Reaman GH.
Phase 2 study of temozolomide in children and adolescents with recurrent
central nervous system tumors: a report from the Children's Oncology Group.
Cancer. 2007 Oct 1;110(7):1542-50.
Abstract
|
|
Eric
Raymond, Karina Vera, Latifa Djafari, Laure Felizot, Sandrine Faivre,
Kamel Djazouli
Safety
profile and activity of high-dose temozolomide given daily x 3 every 2
weeks in patients with primary brain tumors
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
310
|
|
O'Reilly
SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth
RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, et al.
Temozolomide: a new oral cytotoxic
chemotherapeutic agent with promising activity against primary brain
tumours
Eur J Cancer 1993;29A(7):940-2
|
|
Sterba J, Pavelka Z,
Slampa P.
Concomitant radiotherapy and metronomic
temozolomide in pediatric high-risk brain tumors
Neoplasma
2002;49(2):117-20
|
|
R.
Stupp, S. Ostermann, A. Calderoni, C. Uhlmann, S. Leyvraz
Temozolomide (TMZ) and irinotecan (CPT-11) for
primary brain tumors. A dose escalation study
39th ASCO Annual Meeting,
Chicago, IL. May 31-June 3, 2003. Abstract No.
415
|
|
|
Terasaki M, Bouffet E, Katsuki H, Fukushima S,
Shigemori M.
Pilot trial of the rate of response, safety, and tolerability of
temozolomide and oral VP-16 in patients with recurrent or treatment-induced
malignant central nervous system tumors
Surg Neurol.
2008 Jan;69(1):46-50
Abstract |
Links | BL 7:6
|
|
|
Ependymoma |
|
|
|
Riccardo
Soffietti, Alessandra Costanza, Mauro Nobile, Roberta Ruda', Roberto
Mutani
Temozolomide for recurrent ependymomas of the
adult
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract
No.
2078
|
|
|
Glioblastoma
|
|
|
|
|
Affronti
ML, Heery CR, Herndon JE 2nd, Rich JN, Reardon DA, Desjardins A, Vredenburgh
JJ, Friedman AH, Bigner DD, Friedman HS
Overall
survival of newly diagnosed glioblastoma patients receiving carmustine
wafers followed by radiation and concurrent temozolomide plus rotational
multiagent chemotherapy
Cancer. 2009 Jun 9. [Epub
ahead of print]
Abstract |
Links |
Issue
|
|
R
Albright, M Brada, J Brunner, MH Dugan, K Fink, R Fredericks, VA Levin, J
Olson,
M Prados, A Spence, N Yue, A Yung, S Zaknoen
Randomized Trial of Temodal
(TEM) Vs. Procarbazine (PCB) in Glioblastoma
Multiforme (GBM) at First Relapse
ASCO Proceedings, 1999 Annual Meeting, Abstract
|
| |
Carmen
Balaña,
Antonio López-pousa,
Alfonso Berrocal, Ricardo Yaya-tur, Ana Herrero, Jose-luis García,
Javier Martín-broto,
Manuel Benavides, Miguel Cerdá-nicolás,
Rosa Ballester, Josep Balart, Jaume
Capellades
Phase
II study of temozolomide and cisplatin as primary treatment prior to
radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable
disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM)
Journal
of Neuro-Oncology, 70(3):
359-370, December 2004. (Abstract+)
|
| |
Mirco
Bartolomei MD,
Chiara
Grana MD,
Chiara
Mazzetta Bsc, Giulio
Maira MD, Daria
Handkiewicz-Junak MD,
Carmelo
Sturiale MD,
Lisa
Bodei MD, Gaetano
Villa MD, Paola
Rocca MD,
Giovanni
Paganelli MD
Combined Treatment of Glioblastoma Patients
with Locoregional Pre-targeted 90Y-Biotin Radioimmunotherapy and
Temozolomide
The Quarterly Journal of Nuclear Medicine, 2004, Vol. 48, No. 3, September
|
|
Fabian
Baumann, Miroslava Bjeljac, Spyros S. Kollias, Brigitta G. Baumert,
Sebastian Brandner, Valentin Rousson, Yasuhiro Yonekawa, René L. Bernays
Combined Thalidomide and Temozolomide Treatment in Patients with
Glioblastoma Multiforme
Journal of Neuro-Oncology, 67 (1-2): 191-200, March, 2004 - April, 2004 (Abstract+)
|
|
M.
Bjeljac, F. Baumann and R. Bernays
Combined
thalidomide and temozolomide treatment in patients with glioblastoma multiforme
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 451
|
|
A. Boiardi, M. Eoli, A. Salmaggi,
E. Lamperti, A. Botturi, G. Broggi, L. Bissola, G. Finocchiaro
and A. Silvani
Systemic
Temozolomide Combined with Loco-regional Mitoxantrone in Treating Recurrent
Glioblastoma
Journal of Neuro-Oncology, Vol 75, No. 2, November, 2005, Pages 215-220, DOI:
10.1007/s11060-005-3030-x, Online: November 11, 2005
|
|
|
Brada
M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D,
Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N,
Bruner J, Dugan M, Rao S, Zaknoen S.
Multicenter
phase II trial of temozolomide in patients with glioblastoma multiforme at
first relapse
Ann Oncol 2001 Feb;12(2):259-66
|
|
|
Brandes
AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A,
Agati R, Calbucci F, Ermani M
Temozolomide
concomitant and adjuvant to radiotherapy in elderly patients with
glioblastoma: correlation with MGMT promoter methylation status
Cancer. 2009 Jun 9. [Epub
ahead of print]
Abstract |
Links |
Issue
|
|
A A Brandes, A Tosoni, G Cavallo, R Bertorelle, V
Gioia, E Franceschi, M Biscuola, V Blatt, L Crinò and M Ermani
Temozolomide 3 weeks on and 1 week off as
first-line therapy for recurrent glioblastoma: phase II study from gruppo
italiano cooperativo di neuro-oncologia (GICNO)
British Journal of Cancer advance online publication 3 October 2006;
doi:10.1038/sj.bjc.6603376
Abstract
|
|
Alba A. Brandes, Umberto
Basso, Michele Reni, Francesca Vastola, Alicia
Tosoni, Giovanna Cavallo, Luciano Scopece,
Andres J. Ferreri, Maria G. Panucci, Silvio
Monfardini, Mario Ermani
First-Line Chemotherapy With
Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma
Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di
Neuro-Oncologia
Journal of Clinical Oncology, Vol 22, No 9 (May 1), 2004: pp.
1598-1604.
|
|
Alba A. Brandes, M.D.,
Francesca Vastola, M.D., Umberto Basso, M.D., Franco Berti, M.D., Giampietro Pinna, M.D., Antonino Rotilio, M.D., Marina Gardiman, M.D., Renato Scienza, M.D., Silvio Monfardini, M.D., Mario Ermani, M.D.
A
prospective study on glioblastoma in the elderly
Cancer,
Volume
97, Issue 3, 2003 (Jan).
Pages: 657-662
|
|
|
Alba A. Brandes, Mario Ermani, Umberto Basso,
Myriam K. Paris, Franco Lumachi, Franco Berti,
Pietro Amistà, Marina Gardiman, Paolo Iuzzolino,
Sergio Turazzi, Silvio Monfardini
Temozolomide in Patients with Glioblastoma at Second Relapse after First Line
Nitrosourea-Procarbazine Failure: A Phase II Study
Oncology,
Vol. 63, No. 1,
38-41, August 2002
Abstract |
Links | BL
1:3
|
|
|
Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle
KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton
RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C,
Buckner JC
Phase I/II Trial Erlotinib and Temozolomide With Radiation Therapy in the
Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer
Treatment Group Study N0177
J
Clin Oncol. 2008 Oct 27. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
L.
Butttolo, F. Giunta, V. D. Ferrari, G. Marini
Temozolomide
in glioblastoma: 4 years' experience with monthly or fortnigthly schedule
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
|
|
J.
N. Capparella, V. M. Johnson, X. Maestri-Moden, P. Sampath, N. Ready,
L. Alderson
Phase II
trial of daily oral temozolomide and thalidomide in newly diagnosed
glioblastoma multiforme before radiation therapy
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
483
|
|
Alessandra
Cassano, Raffaele Longo, Lucia Angelelli, Marco Ciaparrone, Michela
Quirino, Giovanni Schinzari, Chiara Battelli, Michele Basso, Carmelo
Pozzo, Carlo Barone
Temozolomide
in First Line Treatment of Recurrent or Residual Malignant Brain Tumors
ASCO
Proceedings, 2001 Annual Meeting, Abstract No. 2058
|
|
Marc C. Chamberlain and Lisa Chalmers
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy
in elderly patients with glioblastoma
J Neurooncol. 2006 Oct 4; [Epub
ahead of print]
Abstract
|
|
Susan
M Chang, Martin K Nicholas, David Larson, William Wara, Patricia Sneed,
Michael Prados
Phase II study of concurrent temozolomide
and cis-retinoic acid with radiation for newly diagnosed glioblastoma
multiforme
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
2094
|
|
Chinot OL, Barrie M, Frauger E, Dufour H,
Figarella-Branger D, Palmari J, Braguer D, Hoang-Xuan K, Moktari K,
Peragut JC, Martin PM, Grisoli F
Phase II study of temozolomide without
radiotherapy in newly diagnosed glioblastoma multiforme in an elderly
populations
Cancer. 2004 May 15;100(10):2208-14.
|
|
O.
Chinot, M. Barrie, C. Couprie, H. Dufour, D. Figarella, X. Muracciole,
D. Braguer, K. Hoang-Huan, J.-C. Peragut, F. Grisoli
Preradiation combination of temozolomide (TMZ)
and BCNU as primary treatment before radiotherapy (RT) in inoperable newly
diagnosed glioblastoma multiforme (GBM)
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
431
|
|
Oliver
Chinot, M
Barrie, E Frauger, H Dufour, J Palmari, D Braguer, J. C Peragut, P. M
Martin, F. Grisoli
Phase
II study of temozolomide (TMZ) without radiotherapy in newly diagnosed
glioblastoma multiforme (GBM) in an elderly population
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
308
|
|
|
Susan L. Chua, Mark A. Rosenthal, Shirley S. Wong, David
M. Ashley, Anne-marie Woods, Anthony Dowling, and Lawrence M. Cher
Phase 2 study of temozolomide
and Caelyx in patients with recurrent glioblastoma multiforme
Neuro-Oncology,
January 2004, Volume 6 Number 1, Pages 38 -- 43
|
|
S.
L. Chua, M. A. Rosenthal, D. Ashley, A.-M. Woods, A. Dowling, L. Cher
Combination
temozolomide (T) and pegylated liposomal doxorubicin (C) in patients with
recurrent glioblastoma multiforme (GBM)
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
441
|
|
|
Clarke
JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, Deangelis LM, Hormigo A,
Nolan CP, Gavrilovic I, Karimi S, Abrey LE
Randomized
Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or
Metronomic Temozolomide for Newly Diagnosed Glioblastoma
J
Clin Oncol. 2009 Jun 8. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
Claudia
Collao, Nicolas de Tribolet, Pierre-Yves Dietrich, Serge Leyvraz,
Philippe Maeder, Ivan Maillard, Raymond Miralbell, Rene Mirimanoff,
Sandrine Ostermann Kraljevic, Alessia Pica, Roger Stupp, Jean-Guy
Villemure
Promising Survival with Concomitant and Adjuvant Temozolomide [TMZ] for
Newly Diagnosed Glioblastoma Multiforme [GBM]
ASCO
Proceedings, 2000 Annual Meeting, Abstract No. 632
|
|
|
Combs
SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, Schulz-Ertner D.
Postoperative Treatment of Primary Glioblastoma
Multiforme with Radiation and Concomitant Temozolomide in Elderly Patients.
Int
J Radiat Oncol Biol Phys. 2007 Oct 29; [Epub ahead of print]
Abstract
|
|
|
Stephanie
E Combs, Steffen Heeger, Renate Haselmann, Lutz Edler, Juergen Debus and
Daniela Schulz-Ertner
Treatment of primary glioblastoma multiforme
with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial:
study protocol
BMC Cancer 2006, 6:133; Published: 18 May 2006; doi:10.1186/1471-2407-6-133
Abstract
|
Reprint
|
|
S.
E. Combs, S. Gutwein, D. Schulz-Ertner, M. Van Kampen, C. Thilmann, M.
M. Wannenmacher, J. Debus
Temozolomide combined with radiation as
first-line treatment in primary glioblastoma multiforme: Phase I/II-study
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1531
|
|
Ilda
Costa, Duarte Salgado, Teresa Pimentel, Joao Nunes, M Luz Quintal,
Jose Bravo-Marques
Efficacy and low toxicity of temozolomide
in the treatment of primary brain tumors
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract
No.
2089
|
|
T. J. Doyle, T. Mikkelsen,
D. Croteau, H. Ali, J. Anderson, R.
Beasse, L. Rogers, M. Rosenblum and S.
Ryu
Fatal hematologic toxicity with prolonged continuous administration of
temozolomide (TMZ) during radiation therapy (RT) in the treatment of
newly-diagnosed glioblastoma multiforme (GBM): Report of a Phase II trial
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1546.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement),
2005: 1546
|
|
|
Ducray F, Benouaich-Amiel A, Idbaih A, Rousseau
A, Laigle-Donadey F, Delattre JY, Sanson M.
Complete response after one cycle of temozolomide in an elderly patient
with glioblastoma and poor performance status
J Neurooncol.
2008 Mar 4; [Epub ahead of print]
Abstract |
Links | BL 7:6
|
|
Mario
Ermani, Alba A Brandes, Lara M Pasetto, Umberto Basso, Michele Reni,
Sergio Turazzi, Silvia Berlucchi, Paolo Iuzzolino, Giampietro Pinna, Renato
Scienza, Silvio Monfardini
First
line chemotherapy with cisplatin plus fractionated temozolomide (bid) in
recurrent glioblastoma (GBM)
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
|
|
|
Erpolat
OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S
Outcome of newly diagnosed glioblastoma patients treated by radiotherapy
plus concomitant and adjuvant temozolomide: a long-term analysis
Tumori. 2009 Mar-Apr;95(2):191-7
Abstract |
Links |
Issue
|
|
L.
Fatigante, L. Cionini, A. M. Nocita, M. Luppatelli, A. Tagliagambe, F.
Grillo Ruggeri, L. Pirtoli, A. Paccapelo
Safety and efficacy of temozolomide concomitant
and sequential to radiotherapy in glioblastoma multiforme: Results of a
phase II multicentric study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
424
|
|
|
Franceschi E, Tosoni A, Brandes AA
Adjuvant temozolomide: how long and how much?
Expert
Rev Anticancer Ther. 2008 May;8(5):663-5
Abstract |
Full Text |
Reprint |
Links |
Issue
|
|
E.
Franceschi, L. Scopece, G. Cavallo, R. Degli Esposti, F. Spagnolli, S.
Rimondini, R. Conforti, E. Palmerini, S. Gori, L. Crino
Temozolomide
and cisplatin for the treatment of glioblastoma: A phase II study
39th ASCO Annual
Meeting. Chicago, IL. May 31-June 3, 2003.
|
|
|
Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W,
Kortmann RD, Reifenberger G, Weller M, Herrlinger U
Long-Term
Survival of Patients With Glioblastoma Treated With Radiotherapy and
Lomustine Plus Temozolomide
J
Clin Oncol. 2009 Feb 2. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
|
Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu
VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK
Two phase II trials of temozolomide with interferon-alpha2b (pegylated
and non-pegylated) in patients with recurrent glioblastoma multiforme
Br J Cancer. 2009 Aug 18;101(4):615-20
Abstract |
Links |
Issue
|
|
Morris D. Groves, Vinay K. Puduvalli,
Susan M. Chang, Charles A. Conrad, Mark R. Gilbert,
Ivo W. Tremont-Lukats, Ta-Jen Liu, Pamela Peterson, David Schiff,
Timothy F. Cloughesy, Patrick Y. Wen, Harry Greenberg,
Lauren E. Abrey, Lisa M. DeAngelis, Kenneth R. Hess,
Kathleen R. Lamborn, Michael D. Prados and W. K. Alfred Yung
A North American brain tumor consortium (NABTC 99-04) phase II trial of
temozolomide plus thalidomide for recurrent glioblastoma multiforme
J Neurooncol. 2006 Sep 22; [Epub
ahead of print]
Abstract
|
|
M. D. Groves, V.
Puduvalli, M. R. Gilbert, C. A. Conrad, S.
Hsu, H. Colman, K. Hess, V. A.
Levin and W. K. A. Yung
A phase II study of temozolomide plus pegylated interferon alfa-2b for
recurrent anaplastic glioma and glioblastoma multiforme
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1519
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1519
Abstract
|
|
Groves
MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA.
Phase II trial of temozolomide plus the matrix
metalloproteinase inhibitor, marimastat, in recurrent and progressive
glioblastoma multiforme
J Clin Oncol 2002 Mar 1;20(5):1383-8
|
|
P. Hau,
T. Jauch, B. Hirschmann, E. Drechsel, O. Grauer, H. Koch, C. Wismeth, A.
Steinbrecher, U. Bogdahn
Adjuvant chemotherapy with temozolomide and
pegylated liposomal doxorubicin in the first-line therapy of patients with
glioblastoma – a phase-II trial
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1547
|
|
P.
Hau, T. Jauch, U. Baumgart, O. Grauer, B. Hirschmann, L. Kaes, H.
Koch, C. Wismeth, A. Steinbrecher, U. Bogdahn
Adjuvant
chemotherapy with temozolomide and liposomal doxorubicine in the
first-line therapy of patients with glioblastoma - a phase-II trial
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
471
|
|
Monika E. Hegi, Ph.D.,
Annie-Claire Diserens, M.Sc., Thierry Gorlia, M.Sc., Marie-France Hamou,
Nicolas de Tribolet, M.D., Michael Weller, M.D., Johan M. Kros, M.D.,
Johannes A. Hainfellner, M.D., Warren Mason, M.D., Luigi Mariani, M.D.,
Jacoline E.C. Bromberg, M.D., Peter Hau, M.D., René O. Mirimanoff, M.D.,
J. Gregory Cairncross, M.D., Robert C. Janzer, M.D., and Roger Stupp, M.D.
MGMT
Gene Silencing and Benefit from Temozolomide in Glioblastoma
The New England Journal of Medicine,
Volume 352:997-1003, Number 10, March 10, 2005
Abstract
| BrainLife |
Full Text
|
Reprint |
News
|
|
Monika E. Hegi,
Annie-Claire Diserens, Sophie Godard,
Pierre-Yves Dietrich, Luca Regli,
Sandrine Ostermann, Philippe Otten,
Guy Van Melle, Nicolas de Tribolet
and Roger Stupp
Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA
Methyltransferase Promoter Methylation in Glioblastoma Patients
Treated with Temozolomide
Clinical Cancer Research Vol. 10, 1871-1874, 15 March 2004.
|
|
Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke
B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer
C, Bamberg M, Reifenberger G, Weller M.
Phase II trial of lomustine plus temozolomide chemotherapy in addition to
radiotherapy in newly diagnosed glioblastoma: UKT-03.
J Clin Oncol. 2006 Sep 20;24(27):4412-7.
Abstract
|
|
Keles GE,
Lamborn KR, Chang SM, Prados MD, Berger MS
Volume of residual disease as a
predictor of outcome in adult patients with recurrent supratentorial
glioblastomas multiforme who are undergoing chemotherapy
J Neurosurg. 2004 Jan;100(1):41-6.
|
|
|
Kesari
S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT,
Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM,
Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY.
Phase II study of temozolomide, thalidomide, and celecoxib for newly
diagnosed glioblastoma in adults
Neuro Oncol. 2008 Apr 10; [Epub ahead of print]
Abstract |
Links | BL 7:8
|
|
|
J. Kirkpatrick, A. Desjardins, J. J. Vredenburgh, J. A. Quinn, J. N.
Rich, S. Sathornsumetee, S. Gururangan, A. H. Friedman, H. S. Friedman, D.
A. Reardon
Combination of bevacizumab, a monoclonal antibody to vascular endothelial
growth factor (VEGF), and temozolomide: Study of cases
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 11522
|
|
|
Dorothee Koch, Thomas Hundsberger, Stephan Boor
and Bernd Kaina
Local intracerebral administration of O6-benzylguanine combined
with systemic chemotherapy with temozolomide of a patient suffering from a
recurrent glioblastoma
J Neurooncol. 2006 Sep 20; [Epub
ahead of print]
Abstract
|
|
|
Kocher
M, Frommolt P, Borberg SK, Rühl U, Steingräber M, Niewald M, Staar S,
Stuschke M, Becker G, Fischedick AR, Herfarth K, Grauthoff H, Müller RP
Randomized Study of Postoperative Radiotherapy and Simultaneous Temozolomide
without Adjuvant Chemotherapy for Glioblastoma
Strahlenther
Onkol. 2008 Nov;184(11):572-579. Epub 2008 Nov 19
Abstract |
Links |
Issue
|
|
|
Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham
C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T.
Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and
Regional Radiation Therapy for Up-Front Treatment of Patients With Newly
Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and
Tolerability
Int
J Radiat Oncol Biol Phys. 2008 Mar 20; [Epub ahead of print]
Abstract |
Links | BL 7:7
|
|
Lefranc
F, James S, Camby I, Gaussin JF, Darro F, Brotchi J, Gabius J,
Kiss R
Combined cimetidine and temozolomide, compared with
temozolomide alone: significant increases in survival in nude mice bearing
U373 human glioblastoma multiforme orthotopic xenografts
J
Neurosurg. 2005 Apr;102(4):706-14
|
|
|
Mathieu
V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R,
Lefranc F
Combining bevacizumab with temozolomide increases the antitumor efficacy of
temozolomide in a human glioblastoma orthotopic xenograft model
Neoplasia. 2008 Dec;10(12):1383-92
Abstract |
Full Text |
Reprint |
Links |
Issue
|
|
|
McGirt MJ, Than KD, Weingart JD, Chaichana KL,
Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quiñones-Hinojosa
A
Gliadel
(BCNU) wafer plus concomitant temozolomide therapy after primary resection
of glioblastoma multiforme
J Neurosurg.
2008 Dec 1. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
|
Minniti G, De Sanctis V, Muni R, Filippone F,
Bozzao A, Valeriani M, Osti MF, De Paula U, Lanzetta G, Tombolini V, Maurizi
Enrici R.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
in elderly patients
J Neurooncol. 2008 Feb 5; [Epub ahead of print]
Abstract |
Links | BL 7:4
|
|
|
René-Olivier Mirimanoff, Thierry
Gorlia, Warren Mason, Martin J. Van den Bent,
Rolf-Dieter Kortmann, Barbara Fisher, Michele
Reni, Alba A. Brandes, Jüergen Curschmann,
Salvador Villa, Gregory Cairncross, Anouk
Allgeier, Denis Lacombe, Roger Stupp
Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive
Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized
Trial
J
Clin Oncol. 2006 Jun 1;24(16):2563-9. DOI: 10.1200/JCO.2005.04.5963
Abstract
|
|
|
Nagane M, Kobayashi K, Ohnishi A, Shimizu S,
Shiokawa Y
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein
Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide
Jpn J Clin Oncol. 2007 Dec 21;. [Epub ahead of print]
Abstract |
Links | BL 7:1
|
|
|
Nieder
C, Adam M, Grosu AL
Combined modality treatment of glioblastoma multiforme: the role of
temozolomide
Rev Recent Clin Trials. 2006 Jan;1(1):43-51
Abstract |
Links | BL 7:8
|
|
|
Osoba D, Brada M, Yung WK, Prados M.
Health-related quality of life in patients
treated with temozolomide versus procarbazine for recurrent glioblastoma
multiforme
J Clin Oncol
2000 Apr;18(7):1481-91 (PDF Full Text)
|
|
|
Pan
E, Mitchell SB, Tsai JS
A retrospective study of the safety of BCNU wafers with concurrent
temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed
glioblastoma patients
J Neurooncol.
2008 Apr 4; [Epub ahead of print]
Abstract |
Links | BL 7:8
|
|
|
Panet-Raymond V, Souhami L, Roberge D, Kavan P,
Shakibnia L, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot MC,
Shenouda G
Accelerated Hypofractionated Intensity-Modulated Radiotherapy with
Concurrent and Adjuvant Temozolomide for Patients with Glioblastoma
Multiforme: A Safety and Efficacy Analysis
Int J Radiat Oncol Biol Phys. 2008 Jun 11; [Epub ahead of print]
Abstract |
Links |
BL 7:13
|
|
|
S. Pannullo, S. Hariharan, J.
Serventi, R. Hayes, C. Balmaceda, J. Burton
Phase I/II trial of a twice-daily regimen of
temozolomide and celecoxib for treatment of relapsed/refractory
glioblastoma multiforme and anaplastic astrocytoma
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1549
|
|
S.
Pannullo, J. V. Serventi, C. Balmaceda, J. Burton
Temozolomide plus celecoxib for treatment of
malignant gliomas
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
455
|
|
|
Perry JR, Rizek P, Cashman R, Morrison M,
Morrison T.
Temozolomide rechallenge in recurrent malignant glioma by using a
continuous temozolomide schedule: the "rescue" approach
Cancer. 2008 Aug 28; [Epub ahead of print]
Abstract |
Links | BL 7:18
|
|
Dietrich Pierre
, Serg Leyvraz, Phillip Maeder, Iva Maillard, Raymon Miralbell, Mirimanoff
Rene , Alessi Pica, Roge Stupp, Tribolet Nicolas d, Villemure Jean
Daily Temozolomide (TMZ) and Concomitant
Radiotherapy Followed by Adjuvant TMZ for Newly Diagnosed Glioblastoma
Multiforme (GBM). A Well Tolerated and Promising Regimen
ASCO Proceedings, 1999
Annual Meeting, Abstract
|
|
|
Piroth MD, Gagel B, Pinkawa M, Stanzel S,
Asadpour B, Eble MJ
Postoperative Radiotherapy of Glioblastoma Multiforme : Analysis and
Critical Assessment of Different Treatment Strategies and Predictive Factors
Strahlenther
Onkol. 2007 Dec;183(12):695-702.
Epub 2007 Nov 27
Abstract |
Links
|
|
|
Poelen
J, Prick MJ, Jeuken JW, Wesseling P, Bernsen HJ
Six year survival after prolonged temozolomide treatment in a 30-year-old
patient with glioblastoma
Acta Neurol Belg. 2009 Sep;109(3):238-42
Abstract |
Links |
CNO 8(12)
|
|
|
Michael D. Prados, W.K. Alfred Yung, Howard A. Fine,
Harry S. Greenberg, Larry Junck, Susan M. Chang, M. Kelly Nicholas, H. Ian
Robins, Minesh P. Mehta, Karen L. Fink, Kurt A. Jaeckle, John Kuhn,
Kenneth R. Hess, and S. Clifford Schold Jr.
Phase 2 study of BCNU and temozolomide for
recurrent glioblastoma multiforme: North American Brain Tumor Consortium
study
Neuro-Oncology,
January 2004, Volume 6 Number 1, Pages 33 -- 37
|
|
|
Quinn JA, Jiang SX, Reardon DA, Desjardins A,
Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE 2nd,
Friedman HS
Phase
II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly
diagnosed glioblastoma multiforme before radiotherapy
J Neurooncol.
2009 Jun 17. [Epub ahead of print]
Abstract |
Links |
Issue
|
| |
D. Reardon, H. Friedman, W. K. A. Yung, M. Brada, C. Conrad, J. Provenzale,
E. Jackson, H. Serajuddin, B. Chen, D. Laurent
A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis
inhibitor, in combination with either temozolomide or lomustine for patients
with recurrent glioblastoma multiforme (GBM)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1513
|
|
D.
Reardon, H. S. Friedman, W. K. A. Yung, M. Brada, C. Conrad, J. Provenzale,
E. F. Jackson, H. Serajuddin, D. Laurent, D. Reitsma
A
phase I trial of PTK787/ZK 222584 (PTK/ZK), an oral VEGF tyrosine kinase
inhibitor, in combination with either temozolomide or lomustine for patients
with recurrent glioblastoma multiforme (GBM)
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 412
|
|
Antonio Santoro, Massimiliano
Santoro, Luigi Maiorino
Role of temozolomide (TMZ) for brain relapsed
tumors: preliminary results
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract
No.
2107
|
|
Schold
SC Jr, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM,
Fulton D, Fink KL, Prados MD.
A
phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a
North American Brain Tumor Consortium study
Neuro-oncol
2000 Jan;2(1):34-9
|
|
|
Sher DJ, Henson JW, Avutu B, Hochberg FH,
Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A
The added value of concurrently administered temozolomide versus adjuvant
temozolomide alone in newly diagnosed glioblastoma
J Neurooncol.
2008 Jan 30; [Epub ahead of print]
Abstract |
Links | BL 7:4
|
|
|
Sridhar T, Gore A, Boiangiu I, Machin D, Symonds
RP.
Concomitant (without Adjuvant) Temozolomide and Radiation to Treat
Glioblastoma: a Retrospective Study
Clin Oncol (R Coll Radiol). 2008 Oct 5; [Epub ahead of print]
Abstract |
Links |
BL 7:20
|
|
Roger Stupp, M.D., Warren
P. Mason, M.D., Martin J. van den Bent, M.D., Michael Weller, M.D.,
Barbara Fisher, M.D., Martin J.B. Taphoorn, M.D., Karl Belanger, M.D.,
Alba A. Brandes, M.D., Christine Marosi, M.D., Ulrich Bogdahn, M.D.,
Jürgen Curschmann, M.D., Robert C. Janzer, M.D., Samuel K. Ludwin,
M.D., Thierry Gorlia, M.Sc., Anouk Allgeier, Ph.D., Denis Lacombe, M.D.,
J. Gregory Cairncross, M.D., Elizabeth Eisenhauer, M.D., René O.
Mirimanoff, M.D., for the European Organisation for Research and
Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National
Cancer Institute of Canada Clinical Trials Group
Radiotherapy plus Concomitant
and Adjuvant Temozolomide for Glioblastoma
The New England Journal of Medicine, Volume
352:987-996, Number 10, March 10, 2005
|
|
R.
Stupp, W. P. Mason, M. J. Van Den Bent, M. Weller, B. Fisher, M.
Taphoorn, A. A. Brandes, G. Cairncross, D. Lacombe, R. O. Mirimanoff
Concomitant and adjuvant temozolomide (TMZ) and
radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM).
Conclusive results of a randomized phase III trial by the EORTC Brain
& RT Groups and NCIC Clinical Trials Group
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2
|
|
Stupp R, Dietrich PY, Ostermann
Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G,
Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S.
Promising survival for patients with newly
diagnosed glioblastoma multiforme treated with concomitant radiation plus
temozolomide followed by adjuvant temozolomide
J Clin Oncol 2002 Mar 1;20(5):1375-82
|
|
Roger
Stupp, Sandrine Ostermann Kraljevic, Pierre-Yves Dietrich, Alessia
Pica, Ivan Maillard, Philippe Maeder, Raymond Miralbell, Claudia Collao,
Jean-Guy Villemure, Nicolas de Tribolet, Rene Mirimanoff, Serge Leyvraz
Promising Survival with Concomitant and Adjuvant
Temozolomide [TMZ] for Newly Diagnosed Glioblastoma Multiforme [GBM]
ASCO
Proceedings, 2000 Annual Meeting, Abstract No. 632
|
|
|
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier
AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ,
Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T
Randomized
Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent
Glioblastoma: EORTC Brain Tumor Group Study 26034
J
Clin Oncol. 2009 Feb 9. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
|
van Genugten JA, Leffers P, Baumert BG,
Tjon-A-Fat H, Twijnstra A
Effectiveness
of temozolomide for primary glioblastoma multiforme in routine clinical
practice
J Neurooncol.
2009 Jul 7. [Epub ahead of print]
Abstract |
Full Text |
Reprint |
Links |
Issue
|
|
|
W. Wick, J. P. Steinbach, J.
Schuth, J. Dichgans, M. Bamberg, M. Weller
One week on/one week off regimen of temozolomide
for recurrent glioblastoma: A phase II study
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1536
|
|
|
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence
A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R,
Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA.
A
phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse
Br J
Cancer 2000 Sep;83(5):588-93
|
|
Glioblastoma-Elderly
patients |
|
|
|
Fiorica F, Berretta M, Colosimo C, Stefanelli A,
Ursino S, Zanet E, Palmucci T, Maugeri D, Malaguarnera M, Palmucci S, Grasso
M, Tirelli U, Cartei F
Glioblastoma in elderly patients: Safety and efficacy of adjuvant
radiotherapy with concomitant temozolomide
Arch Gerontol Geriatr. 2009 Jul 21;. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
|
Laigle-Donadey
F, Figarella-Branger D, Chinot O, Taillandier L, Cartalat-Carel S, Honnorat
J, Kaloshi G, Delattre JY, Sanson M
Up-front temozolomide in elderly patients with glioblastoma
J Neurooncol. 2010 Jan 8;. [Epub ahead of print]
Abstract |
Links |
CNO 9(2)
|
|
|
Gliomas (High-Grade) |
|
|
|
T. Ahmed, B. Chen,
G. Rabbani, M. N. Wallam and D. Benzil
Phase II trial of thalidomide (TD), tamoxifen
(TX), and temozolomide (T) for patients with advanced malignant gliomas (MG)
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1575.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement),
2005: 1575
|
|
P.
Amistà, A. Brandes, L. Coria, M. Ermani, B. Guglielmi, S. Maluta, S.
Monfardini, L. Pasetto, G. Pinna, R. Scienza, G. Sotti, S. Turazzi
Temozolomide (TMZ) in High Grade Gliomas (HGG)
at Second Relapse: a Phase II Study
ASCO
Proceedings, 2000 Annual Meeting, Abstract No. 646
|
|
M.
A. Badruddoja, D. Reardon, R. Beason, A. Friedman, J. A. Quinn, J.
Rich, J. Sampson, V. Stafford-Fox, D. D. Bigner, H. S. Friedman
Phase
1 study of temozolomide plus irinotecan (CPT-11) in adults with recurrent
malignant glioma
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
409
|
|
|
Balmaceda C, Peereboom D, Pannullo S, Cheung YK,
Fisher PG, Alavi J, Sisti M, Chen J, Fine RL.
Multi-institutional phase II study of temozolomide administered twice
daily in the treatment of recurrent high-grade gliomas
Cancer. 2008 Feb 1; [Epub ahead of print]
Abstract |
Links | BL 7:4
|
|
Casilda
Balmaceda, C De Rosa, K Peterson, D Peerboom, J Alavi, M Fetell, H
Krouwer, S Panullo, E Bagiella, S Weaver, L McAllister, L Heller, R Fine
Multi-Institutional
Trial of BID Regimen of Temozolomide for Recurrent Malignant Gliomas
ASCO Proceedings, 2001
Annual Meeting, Abstract No. 257
|
|
Giuseppe Luigi Banna, Daniela Bettio,
Marta Scorsetti, Pierina Navarria, Matteo Simonelli, Riccardo Rodriguez
Baena, Enrico Aimar, Paolo Gaetani, PierGiuseppe Colombo, Felice Rognone
and Armando Santoro
Administration of temozolomide during and after radiotherapy for newly
diagnosed high-grade gliomas excluding glioblastoma multiforme
J Neurooncol. 2006 Sep 23; [Epub
ahead of print]
Abstract
|
|
J.
Baram, R. Pffefer, D. Nass, Z. Ram
Temozolomide for patients with relapsed high grade
gliomas
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
|
|
|
Berrocal A, Perez Segura P, Gil M, Balaña C,
Garcia Lopez J, Yaya R, Rodríguez J, Reynes G, Gallego O, Iglesias L; GENOM
Cooperative Group
Extended-schedule dose-dense temozolomide in refractory gliomas
J Neurooncol.
2009 Aug 8. [Epub ahead of print]
Abstract |
Full Text |
Reprint |
Links |
Issue
|
|
Alfonso
Berrocal, Gaspar Reynes, Maria Jose Safont, Angel Segura, Ana Yuste,
Ramon de las Peñas, Ana Albert, Pedro Lopez, Enrique Barrajon, Cristina
Gonzalez-Junco
Temozolamide as Second Line
Chemotherapy in the Treatment of Recurrent Malignant Gliomas
ASCO
Proceedings, 2001 Annual Meeting, Abstract No. 2053
|
|
Corrado
Boni, Cesare Calandri, Carmine Carapella, Lucio Crino, Samir Darwish,
Antonio Frassoldati, Rolando Gagliardi, Francesca Marrocolo, Andrea Pace,
Federica Spagnolli, Davide Tassinari
Temozolomide
as Second Line Chemotherapy in the Treatment of Recurrent Malignant Gliomas
ASCO
Proceedings, 2000 Annual Meeting, Abstract No. 653
|
|
|
Bower
M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I,
Lewis P, Brampton MH.
Multicentre
CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
Cancer
Chemother Pharmacol 1997;40(6):484-8
|
|
|
M.
Brada, L. Viviers, C. Abson, F. Hines, J. Britton, S. Ashley, S.
Sardell, D. Traish, A. Gonsalves, P. Wilkins and C. Westbury
Phase II study of primary temozolomide
chemotherapy in patients with WHO grade II gliomas
Annals of Oncology 14:1715-1721,
December 2003
|
|
Brada
M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan
M, Batra V, Cutler D.
Phase I dose-escalation and
pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing
malignancies
Br
J Cancer 1999 Nov;81(6):1022-30
|
|
MH
Brampton, C Brock, H Evans, ES Newlands, JK Porteous, SR Wedge
Temozolomide: drug scheduling in vivo and in combination with radiation
ASCO
Proceedings, 1997
Annual Meeting, Abstract
|
|
|
Brandes AA, Ermani M, Basso U,
Amista P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini
S.
Temozolomide
as a second-line systemic regimen in recurrent high-grade glioma: a phase
II study
Ann Oncol 2001 Feb;12(2):255-7
|
|
Brock
CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M,
Glaser M, Brampton MH, Rustin GJ.
Phase
I trial of temozolomide using an extended continuous oral schedule
Cancer Res 1998 Oct 1;58(19):4363-7
|
|
Volker
Budach, Markus Fitzek, Dirk Geismar, Andreas Kaiser, Manfred Koerner,
Lutz Roeschel, Dirk Scheffler, Lorenz Schlenger, Brit Sommer, Maria
Steingraeber, Martin Stuschke, Reinhard Wurm
Phase I-II Study with Continuous
Dose-Escalated 21 Day Schedule Temozolomide in Recurrent High-Grade Glioma
ASCO
Proceedings, 2000 Annual Meeting, Abstract No. 634
|
|
Chang SM, Prados MD, Yung WK, Fine H, Junck L,
Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K,
Schold C
Phase II study of neoadjuvant 1, 3-bis
(2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed
anaplastic glioma: a North American Brain Tumor Consortium Trial
Cancer. 2004 Apr 15;100(8):1712-6.
|
|
Chang SM, Theodosopoulos P, Lamborn K, Malec M,
Rabbitt J, Page M, Prados MD
Temozolomide in the treatment of recurrent
malignant glioma
Cancer. 2004 Feb 1;100(3):605-11.
|
|
S.
M. Chang, W. K. A. Yung, J. Kuhn, D. Schiff, H. Fine, M. Mehta, I.
Robins, L. Junck, K. Hess, M. Prados
Phase II study of neoadjuvant BCNU and temozolomide
for newly diagnosed anaplastic glioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
413
|
|
S. Chibbaro,
L. Benvenuti, A. Caprio, S. Carnesecchi, F. Pulerà, F. Faggionato, D.
Serino, C. Galli, M. Andreuccetti, N. Buxton and R. Gagliardi
Temozolomide as first-line agent in treating
high-grade gliomas: phase II study
J Neurooncol. 2004 Mar-Apr;67(1-2):77-81. (Abstract+)
|
|
Petr
Cypro, Jana Prausova, Bela Malinova, Vladimir Spurny, Karel Odrazka
Concomitant
Chemoradiotherapy with Temozolomide and Temozolomide Alone in the
Treatment of High-Grade Gliomas
ASCO Proceedings, 2001
Annual Meeting, Abstract No. 2050
|
|
|
Dall'oglio S, D'Amico A, Pioli F, Gabbani M,
Pasini F, Passarin MG, Talacchi A, Turazzi S, Maluta S.
Dose-intensity temozolomide after concurrent chemoradiotherapy in
operated high-grade gliomas
J Neurooncol. 2008 Aug 8; [Epub ahead of print]
Abstract |
Links |
BL 7:16
|
|
E.
N. Ebeid, M. S. Zaghloul, A. Khairy, M. Zamzam, I. Sidhom, A. Saber
New therapeutic strategies in pediatric brain
gliomas
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
486
|
|
Els
Everaert, Bart Neyns,
Eric Joosens, Theo Strauven, Fabrice Branle, Johan
Menten
Temozolomide
for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate
use Program in Belgium
J Neurooncol, 70(1):37-48, Oct 2004. (Abstract+)
|
|
Klaus
Fabel, Peter Hau, Oliver Grauer, Tanya Jauch, Martin Proescholdt, Anton
Zellner, Andreas Steinbrecher, Alexander Brawanski, Ulrich Bogdahn
Neoadjuvant therapy with temozolomide and
13-cis-retinoic acid in high grade glioma - a phase II-study
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
|
|
Allan
H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra
Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason,
Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn,
Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D
Bigner, Henry Friedman
Novel use of Gliadel for gliomas
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
|
|
Henry
S Friedman, James Pluda, Jon Weingart, Henry Brem, Brandon Evans, William
Petros, Jeremy Rich, Sandra Tourt-Uhlig, Sridharan Gururangan, David Reardon,
John Sampson, Allan Friedman, James Provenzale, Roger McLendon, O. M Colvin,
Darell D Bigner, M. E Dolan, Anthony Pegg, Robert Moschel, Jennifer Quinn
Phase I trial of temodar plus O6-benzylguanine
in the treatment of patients with recurrent or progressive cerebral anaplastic
gliomas
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
|
|
|
Friedman
HS, Kerby
T, Calvert
H
Temozolomide and treatment of malignant glioma
Clin
Cancer Res. 2000 Jul;6(7):2585-97
Abstract |
Full Text |
Reprint |
Links |
Issue
|
|
|
Friedman HS,
McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J,
Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin
OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL
DNA
mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response
to Temodal in newly diagnosed malignant glioma
J Clin Oncol 1998 Dec;16(12):3851-7
|
|
Gander
M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Lienard D,
Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci
M.
Sequential administration of temozolomide and
fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood
lymphocytes and in tumours
Ann Oncol 1999 Jul;10(7):831-8
|
|
M.
R. Gilbert, P. Wen, F. Lieberman, I. Robins, M. Mehta, W. K. A. Yung, S.
Chang, L. Junck, T. Cloughesy, M. Prados
Phase I/II study of combination temozolomide
(TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: A North
American Brain Tumor Consortium (NABTC) study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
410
|
|
|
Gilbert
MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen
SL
A
phase II study of temozolomide in patients with newly diagnosed
supratentorial malignant glioma before radiation therapy
Neuro-oncol. 2002 Oct;4(4):261-7
|
|
Maria
Gonzalez Cao, Javier Aristu, Marta Santisteban, Jose M Ordonez, Jose M
Aramendia, Ignacio Bilbao, Oscar Fernandez, Salvador Martin Algarra
Phase
II trial of BCNU, temozolamide (TMZ) plus intraarterial cisplatin (CDDP) in
unresectable or recurrent high grade glioma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract
No.
2099
|
|
Michael
L. Gruber, Deborah B Gruber
Phase
II Treatment of Recurrent Malignant Astrocytoma with Temozolomide and
Irinotecan
ASCO Proceedings, 2001
Annual Meeting, Abstract No. 2043
|
|
Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA,
Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH,
Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS.
Phase
I study of Gliadel wafers plus temozolomide in adults with recurrent
supratentorial high-grade gliomas
Neuro-oncol 2001
Oct;3(4):246-50
|
|
|
Hart MG, Grant R, Garside R, Rogers G,
Somerville M, Stein K.
Temozolomide for high grade glioma
Cochrane Database Syst Rev. 2008 Oct 8; (4):CD007415
Abstract |
Links |
BL 7:20
|
|
|
Huang F, Kavan P, Guiot MC, Markovic Y, Roberge
D
When temozolomide alone fails: adding procarbazine in salvage therapy of
glioma
Can J Neurol Sci. 2008 May;35(2):192-7
Abstract |
Links |
BL 7:13
|
|
G.
G. Huidobro Vence, M. Valladares, S. Candamio, C. Grande, R. Garcia
Campelo, R. Garcia Arroyo, M. Ramos, S. Vazquez, J. Cueva, J. L. Firvida
A
study of temozolomide in the treatment of recurrent high-grade gliomas in
Galicia
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract
No. 472
|
|
Jaeckle
KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn
J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M; North
American Brain Tumor Consortium
Phase
II evaluation of temozolomide and 13-cis-retinoic acid for the treatment
of recurrent and progressive malignant glioma: a North American Brain
Tumor Consortium study
J Clin Oncol. 2003 Jun 15;21(12):2305-11
|
|
|
Janinis
J, Efstathiou E, Panopoulos C, Samantas E, Aravantinos G,
Christodoulou C, Skarlos D.
Phase II study of temozolomide in patients with
relapsing high grade glioma and poor performance status
Med
Oncol 2000 May;17(2):106-10
|
|
|
Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE
A
phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Neuro-oncol
2002 Jan;4(1):39-43
|
|
Raja
B Khan, Jeffrey R Raizer, Mark G Malkin, Kimberley A Bazylewicz,
Lauren E Abrey
A
Phase II Study of Extended, Low Dose Temozolomide in Recurrent Gliomas
ASCO
Proceedings, 2001 Annual Meeting, Abstract No. 249
|
|
D.
Korones, M. Benita-Weiss, T. E. Coyle, P. Bushunow, L. Mechtler, H. S.
Friedman
A
phase II trial of temozolomide and oral VP-16 for adults with recurrent
malignant glioma
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
447
|
|
Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P,
Evans B, Reardon DA, Quinn JA, Friedman H
Phase
I study of temozolomide and escalating doses of oral etoposide for adults
with recurrent malignant glioma
Cancer 2003 Apr 15;97(8):1963-8
|
|
David
N Korones, Michal Benita-Weiss, Lazlo Mechtler, Peter Bushunow,
Brandon L Evans, Henry S Friedman
A
phase I study of temozolomide (Temodar) and escalating doses of oral VP-16
for adults with recurrent malignant glioma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. 2080
|
|
David
N Korones, Michal Benita-Weiss, Lazlo Mechtler, Peter Bushunow, Henry
S Friedman
A Phase 1 Study of Temozolomide (Temodar) and
Escalating Doses of Oral VP-16 for Adults with Recurrent Malignant Gliomas
ASCO Proceedings, 2001
Annual Meeting, Abstract No. 2055
|
|
|
Lashford
LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F,
Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D.
Temozolomide
in Malignant Gliomas of Childhood: A United Kingdom Children's Cancer
Study Group and French Society for Pediatric Oncology Intergroup Study
J Clin Oncol 2002 Dec 15;20(24):4684-91
|
|
|
Loghin ME, Prados MD, Wen P, Junck L, Lieberman
F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T,
Deangelis LM, Robins IH, Aldape KD, Yung WK
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant
Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North
American Brain Tumor Consortium Study
Clin
Cancer Res. 2007 Dec 1;13(23):7133-8
Abstract |
Links
|
|
E.
Lopez Aguilar, S. Delgado-Huerta, A. C. Sepulveda-Vildosola, V.
Wanzke-Del-angel, H. Rodriguez-Jimenez
Neoadjuvant chemotherapy with
temozolamide plus ifosfamide, carboplatin and etoposide in pediatric
patients with high grade astrocytomas. Phase II study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
463
|
|
Marzolini
C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T,
Biollaz J, Lejeune F.
Pharmacokinetics
of temozolomide in association with fotemustine in malignant melanoma and
malignant glioma patients: comparison of oral, intravenous, and hepatic
intra-arterial administration
Cancer
Chemother Pharmacol 1998;42(6):433-40
|
|
Newlands
ES, Foster T, Zaknoen S
Phase
I study of temozolomide (TMZ) combined with procarbazine (PCB) in patients
with gliomas
Br J Cancer. 2003 Jul 21;89(2):248-51
|
|
|
Newlands
ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH,
Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG.
The Charing Cross Hospital experience with
temozolomide in patients with gliomas
Eur J Cancer 1996 Dec;32A(13):2236-41
|
|
|
B. Neyns, E. Everaert, E.
Joosens, T. Strauven, F. Branle, J. Menten
Temozolomide for the treatment of recurrent
glioma: Results of a compassionate use program in Belgium
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1541
|
|
|
C. Nieder, N. Wiedenmann, S.
Stark, A. L. Grosu
Phase II trial of functional imaging-optimized
stereotactic fractionated radiotherapy plus temozolomide for recurrent
high-grade glioma
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1552
|
|
|
Oshiro
S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T
Efficacy of Temozolomide Treatment in Patients with High-grade Glioma
Anticancer Res. 2009 Mar;29(3):911-7
Abstract |
Full Text |
Reprint |
Links |
Issue
|
|
|
Osoba
D, Brada M, Yung WK, Prados MD.
Health-related
quality of life in patients with anaplastic astrocytoma during treatment
with temozolomide
Eur J Cancer 2000 Sep;36(14):1788-95
|
|
|
A. Pace, A. Pompili, M.
Maschio, E. Galie', S. Telera, B. Jandolo, E. Occhipinti, C. M. Carapella
PCV and/or TMZ chemotherapy in 255 gliomas.
Analysis of the clinical experience from a neuro-oncology data-base
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1538
|
|
A. Pace, A. Vidiri, E. Galiè, M. Carosi, S. Telera, A. M. Cianciulli,
P. Canalini, D. Giannarelli, B. Jandolo and C. M. Carapella
Temozolomide
chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response
Annals of Oncology 14:1722-1726, December 2003
|
|
A.
Pace, E. Galie', M. Maschio, M. A. Carosi, A. M. Cianciulli, D.
Giannarelli, B. Jandolo, A. Vidiri, C. M. Carapella
Temozolomide
chemotherapy for progressive low grade glioma
39th ASCO Annual
Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 427
|
|
M. Prados, W. Yung, P. Wen, L.
Junck, K. Fink, T. Cloughesy, I. Robins, S. Chang, J. Kuhn
Phase I study of ZD1839 plus temozolomide in
patients with malignant glioma. A study of the North American Brain Tumor
Consortium
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1504
|
|
M.
Prados, S. Chang, E. Burton, A. Kapadia, J. Rabbitt, M. Page, A. Federoff,
S. Kelly, G. Fyfe
Phase I study of OSI-774
alone or with temozolomide in patients with malignant glioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003.
|
|
|
Quinn
JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S,
Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS
Phase
1 trial of temozolomide plus irinotecan plus O(6)-benzylguanine in adults
with recurrent malignant glioma
Cancer. 2009 Apr 28. [Epub
ahead of print]
Abstract |
Links |
Issue
|
|
|
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN,
Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE
2nd, Walker A, Friedman HS
Phase
II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent,
Temozolomide-Resistant Malignant Glioma
J
Clin Oncol. 2009 Feb 9. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
J.
A. Quinn, J. Weingart, H. Brem, J. Rich, D. Reardon, J. Sampson, A.
Friedman, H. S. Friedman, O. M. Colvin, E. Dolan
Phase I trial of temozolomide plus O6-benzylguanine
in the treatment of patients with recurrent or progressive cerebral
anaplastic gliomas
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
411
|
|
Jeffrey J. Raizer,
Mark G. Malkin, Martin Kleber, Lauren E. Abrey
Phase 1 study of 28-day, low-dose
temozolomide and BCNU in the treatment of malignant gliomas after
radiation therapy
Neuro-Oncology, Vol. 6, No. 3, July
2004, 247 -- 252. (Abstract+)
|
|
J.
J. Raizer, M. Kleber, M. G. Malkin, L. E. Abrey; Memorial
Sloan-Kettering Cancer Center, New York, NY
A
phase I trial of extended daily dosing of temozolomide and BCNU for
malignant gliomas after radiation therapy
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
414
|
|
|
Reardon DA, Desjardins A, Vredenburgh JJ,
Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S,
McLendon R, Herndon Ii JE, Friedman AH, Salvado AJ, Friedman HS.
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus
temozolomide: Phase 1 trial in adults with malignant glioma
Neuro Oncol. 2008 Mar 21; [Epub ahead of print]
Abstract |
Links | BL 7:7
|
|
|
Schafer U, Micke O, Schuller P, Schuck
A, Willich N
The effect of sequential radiochemotherapy in
preirradiated malignant gliomas in a phase II study
J Neurooncol. 2004 Mar-Apr;67(1-2):233-9.(Abstract+)
|
|
Antonio
Silvani, Marica Eoli, Andrea Salmaggi, Elena Lamperti, Elio
Maccagnano, Giovanni Broggi, Amerigo Boiardi
Phase
II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive
Malignant Glioma Patients
Journal of Neuro-Oncology, 66 (1-2): 203-208, January 2004 (Abstract+)
|
|
R.
Soffietti, A. Costanza, E. Laguzzi, M. Nobile, R. Rudà;
A phase II study of first-line temozolomide
and second-line PCV in recurrent/progressive malignant gliomas
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1574
|
|
Alexander
M. Spence, Richard A. Peterson, Jeffrey D. Scharnhorst, Daniel L. Silbergeld,
Robert C. Rostomily
Phase
II Study of Concurrent Continuous Temozolomide (TMZ) and Tamoxifen (TMX) for
Recurrent Malignant Astrocytic Gliomas
J Neurooncol,
70(1):91-95, Oct 2004. (Abstract+)
|
|
S.
Tafuto, R. Guarrasi, A. Tortoriello, F. Buzzi, P. Muto, R. Formato, P.
Comella, P. De Rosa, R. V. Iaffaioli, S. Quattrin
Temozolomide (TMZ) and lomustine (CCNU) in high
grade glioma (HGG) patients: Phase I study
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1577
|
|
Philip
V Theodosopoulos, Kathleen R Lamborn, Mary Malec, Margaretta Page,
Jane Rabbitt, Michael P Prados, Susan M Chang
Temozolomide in the Treatment of
Recurrent Malignant Glioma
ASCO
Proceedings, 2001 Annual Meeting,
Abstract No. 2059
|
|
|
A. Tosoni, MD,
G. Cavallo, MD, M. Ermani, MD, L. Scopece,
MD, E. Franceschi, MD, C. Ghimenton, MD, M.
Gardiman, MD, L. Pasetto, MD, V. Blatt, DM
and A. A. Brandes, MD
Is protracted low-dose temozolomide
feasible in glioma patients?
Neurology 66:427-429, 14 Feb
2006
Abstract
| BrainLife
|
News
|
|
Sandra
Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney
Beason, Brandon Evans, Sridharan Gururangan, Allan Friedman, Susanne
Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson,
Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman
Treatment of adults with recurrent
malignant glioma using temozolomide plus CPT-11: a phase I study
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
2096
|
|
Sandra
Tourt-Uhlig,
Jennifer A. Quinn, Jeremy N. Rich, David A. Reardon, John H. Sampson,
James M. Provenzale, Roger E. McLendon, Shari Edwards, Sridharan
Gururangan, Mary L. Affronti, Waynette Buchanan, Susanne Jackson, Deborah
Allen, Kara Penne, Christy Lentz, Darell D. Bigner, Michael Haglund, Allan
H. Friedman, Nicholas Avgeropoulos, David Korones, Valerie Stafford-Fox,
Sara Zaknoen, Henry S. Friedman
Phase II Trial of Temozolomide (Temodar®)
in Patients with Progressive or Recurrent Low Grade Glioma
ASCO
Proceedings, 2001 Annual Meeting,
Abstract No. 2052
|
|
|
Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A,
Hines F, Brada M.
Temozolomide
as second-line chemotherapy for relapsed gliomas
J Neurooncol. 2002 May;57(3):247-51
Abstract |
Reprint |
Links | BL 1:1
|
|
K.
Vera, M. Osorio, L. Djafari, S. Faivre, L. Felizot, H. Hamidou, K.
Djazouli, E. Raymond
Preliminary evidence of antitumor activity of
daily x 3 high-dose oral temozolomide every 2 weeks in patients with
malignant glioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
482
|
|
Wolfgang
Wagner, Klaus-Gregor Schönekaes, Ulrich Niewöhner-Desbordes, Jan
Bennts, Joachim-Hermann Hartlapp
First Results of Combined Radio-Chemotherapy
with Temozolomide on Patients with Recurrent High Grade Glioma
ASCO
Proceedings, 2001 Annual Meeting,
Abstract No. 236
|
|
|
Wick
W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC,
Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T,
Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of
Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or
Temozolomide
J Clin Oncol. 2009 Nov 9;. [Epub ahead of print]
Abstract |
Links |
CNO 8(12)
|
|
|
Wick A, Pascher C, Wick W, Jauch T, Weller M,
Bogdahn U, Hau P
Rechallenge with temozolomide in patients with recurrent gliomas
J Neurol. 2009 Feb 25; [Epub ahead of print]
Abstract |
Links |
Issue
|
|
|
Yung
WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS,
Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N,
Dugan M, Zaknoen S, Levin VA.
Multicenter phase II trial of temozolomide in
patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at
first relapse. Temodal Brain Tumor Group
J
Clin Oncol 1999 Sep;17(9):2762-71
|
|
|
Ziobro M, Rolski J, Grela-Wojewoda A, Zygulska
A, Niemiec M.
Effects of palliative treatment with temozolomide in patients with
high-grade gliomas
Neurol Neurochir Pol. 2008 May-June;42(3):210-215
Abstract |
Full Text |
Reprint |
Links |
BL 7:15
|
|
|
Gliomas
(Low-Grade) |
|
|
|
Charlotte
Abson, Susan Ashley, Michael Brada, Juliet Britton, Frances Hines,
Louis Viviers
A
Phase II Trial of Primary Chemotherapy with Temozolomide in Patients with
Low-Grade Cerebral Gliomas
ASCO Proceedings, 2000 Annual Meeting, Abstract No. 648
|
|
M. Brada, L. Viviers,
C. Abson, F. Hines, J. Britton, S.
Ashley, S. Sardell, D. Traish, A.
Gonsalves, P. Wilkins and C. Westbury
Phase II study of primary
temozolomide chemotherapy in patients with WHO grade II gliomas
Annals of Oncology 14:1715-1721, 2003. (PDF Full Text)
|
|
Paul Brown, Jan Buckner
Temozolomide: Too Early for Definitive Conclusions
Journal of Clinical Oncology, Vol 21, Issue 19 (October 1),
2003: 3710. (Reference+)
|
|
|
Chamberlain MC.
Temozolomide for recurrent low-grade spinal cord gliomas in adults
Cancer. 2008 Jul 9. [Epub
ahead of print]
Abstract |
Links |
BL 7:15
|
|
Hugues Duffau, Luc Taillandier
and Laurent Capelle
Radical
surgery after chemotherapy: a new therapeutic strategy to envision in grade
II glioma
Journal of Neuro-Oncology,
Vol 80, No 2, Nov 2006, Pages 171-176, DOI: 10.1007/s11060-006-9168-3. Published
online: 28 April 2006
|
|
K. Hoang-Xuan, L. Capelle, M.
Kujas, S. Taillibert, H. Duffau, J.
Lejeune, M. Polivka, E. Crinière, Y.
Marie, K. Mokhtari, A.F. Carpentier, F.
Laigle, J.M. Simon, P. Cornu, P.
Broët, M. Sanson, J.Y. Delattre
Temozolomide As Initial Treatment for Adults With Low-Grade
Oligodendrogliomas or Oligoastrocytomas and Correlation With
Chromosome 1p Deletions
Journal of Clinical Oncology, Vol 22, No 15 (August 1), 2004:
pp. 3133-3138.
|
|
|
Kesari
S, Schiff D, Drappatz J, Lafrankie D, Doherty L, Macklin EA, Muzikansky A,
Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G,
Ramakrishna N, Black PM, Wen PY
Phase
II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Clin
Cancer Res. 2009 Jan 1;15(1):330-337
Abstract |
Links |
Issue
|
|
A. Pace, A. Vidiri,
E. Galiè, M. Carosi, S. Telera, A.
M. Cianciulli, P. Canalini, D. Giannarelli,
B. Jandolo and C. M. Carapella
Temozolomide chemotherapy for
progressive low-grade glioma: clinical benefits and radiological response
Annals of Oncology 14:1722-1726, December 2003.
|
|
Nader Pouratian, Jaime Gasco,
Jonathan H. Sherman, Mark E. Shaffrey and David Schiff
Toxicity and efficacy of
protracted low dose temozolomide for the treatment of low grade gliomas
J Neurooncol. 2006 Nov 3; [Epub
ahead of print]. DOI: 10.1007/s11060-006-9280-4
|
|
Jennifer A. Quinn,
David A. Reardon, Allan H. Friedman, Jeremy
N. Rich, John H. Sampson, James M.
Provenzale, Roger E. McLendon, Sridharan
Gururangan, Darell D. Bigner, James E.
Herndon, II, Nicholas Avgeropoulos, Jonathan
Finlay, Sandra Tourt-Uhlig, Mary Lou
Affronti, Brandon Evans, Valerie
Stafford-Fox, Sara Zaknoen, Henry S.
Friedman
Phase II Trial of Temozolomide in
Patients With Progressive Low-Grade Glioma
Journal of Clinical Oncology, Vol 21, Issue 4 (February 15),
2003: 646-651. (Abstract+)
|
|
Nader Pouratian, Jaime Gasco,
Jonathan H. Sherman, Mark E. Shaffrey and David Schiff
Toxicity and efficacy of
protracted low dose temozolomide for the treatment of low grade gliomas
J Neurooncol. 2006 Nov 3; [Epub
ahead of print]. DOI: 10.1007/s11060-006-9280-4
|
|
|
Schiff
D.
Temozolomide and Radiation in Low-Grade and Anaplastic Gliomas:
Temoradiation.
Cancer Invest.
2007 Oct 18;:1-9 [Epub ahead of print]
Abstract
|
|
|
Tosoni
A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA
Temozolomide three weeks on and one week off as first line therapy for
patients with recurrent or progressive low grade gliomas
J Neurooncol.
2008 Apr 23; [Epub ahead of print]
Abstract |
Links | BL 7:9
|
|
P. Y. Wen, D. Schiff,
L. Doherty, D. Gigas, A. Musikansky,
J. Bradshaw, B. Levy, S. Kesari, N.
Ramakrishna, E. Maher and P. Black
A phase II study of prolonged daily
temozolomide for low-grade glioma
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1505.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement),
2005: 1522
|
|
|
Gliomatosis
Cerebri
|
|
|
|
M.
Sanson, K. Djazouli, L. Djafari, M. Napolitano, H. Gervais, K. Hoang-Xuan,
K. Mokhtari, J. Cougnard, A. Hasbini, J.-Y. Delattre
Up-front chemotherapy temozolomide in the
treatment of Gliomatosis Cerebri: Analysis of 33 patients
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
458
|
|
|
Malignant
Lymphoma
|
|
|
|
B.
Evans, J. Quinn, D. Reardon, J. Rich, S. Gururangan, A. Friedman, R.
McLendon, S. Tourt-Uhlig, V. Stafford-Fox, H. S. Friedman
Phase II treatment of adults with newly diagnosed,
progressive or recurrent primary central nervous system lymphoma with
temozolomide
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
438
|
|
|
Omuro AM, Taillandier L, Chinot O, Carnin C,
Barrie M, Hoang-Xuan K.
Temozolomide and methotrexate for primary central nervous system lymphoma
in the elderly
J Neurooncol.
2007 Nov;85(2):207-11.
Epub 2007 Sep 21
Abstract |
Links | BL 7:6
|
|
|
Metastatic
Tumors
|
|
|
|
Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N,
Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM
Temozolomide for the treatment of brain
metastases associated with metastatic melanoma: a phase II study
J Clin Oncol. 2004 Jun 1;22(11):2101-7.
|
|
M. Caraglia, R. Addeo, R.
Costanzo, L. Montella, V. Faiola, E. Capasso, S. Del Prete
Pegylated liposomal doxorubicin plus
temozolamide in the salvage treatment of brain metastases: The update
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1576
|
|
|
Christos Christodoulou,
Dimitrios Bafaloukos, Helen Linardou,
Gerassimos Aravantinos, Aristotelis Bamias,
Maria Carina, George Klouvas and
Dimosthenis Skarlos
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with
brain metastases from solid tumors: a Hellenic Cooperative Oncology
Group (HeCOG) Phase II study
Journal
of Neuro-Oncology, 71(1):
61-65, January 2005. (Abstract+)
|
|
Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ,
Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN
Temozolomide plus thalidomide in patients with brain
metastases from melanoma
Cancer.
2005 Apr 28; [Epub ahead of print]
|
|
|
Iwamoto
FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT,
Abrey LE.
A phase II trial of vinorelbine
and intensive temozolomide for patients with recurrent or progressive brain
metastases.
J Neurooncol.
2007 Nov 7; [Epub ahead of print]
Abstract
|
|
|
Kouvaris
JR, Miliadou A, Kouloulias VE, Kolokouris D, Balafouta MJ, Papacharalampous
XN, Vlahos LJ.
Phase II Study of Temozolomide and Concomitant Whole-Brain Radiotherapy in
Patients with Brain Metastases from Solid Tumors.
Onkologie. 2007
Jul;30(7):361-6. Epub 2007 Jun 27.
PMID: 17596744 [PubMed - in process]
|
|
T.
H. Davis, C. E. Fadul, M. J. Glantz, L. L. Lewis, P. R. Bouchard, T. M.
Bator, J. L. Gonzalez, A. C. Mamourian, B. F. Cole
Pilot phase II trial of temozolomide for
leptomeningeal metastases: Preliminary report
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
460
|
|
S.
Del Prete, M. Caraglia, R. Addeo, R. Costanzo, V. Faiola, G. Facchini
Pegylated
liposomal doxorubicin plus temozolamide in the salvage treatment of brain
metastases: A feasibility study
39th ASCO Annual
Meeting. Chicago, IL. May 31-June 3, 2003.
|
|
H.
S. Friedman, B. Evans, D. Reardon, J. Quinn, J. Rich, S. Gururangan, V.
Stafford-Fox, C. Chen, A. Pati, W. Schmidt
Phase II trial of temozolomide for patients with
progressive brain metastases
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
408
|
|
Sewa S. Legha
Treatment of brain metastases from
melanoma
Journal of Clinical Oncology, Vol 23, No
13 (May 1), 2005: pp. 3155. (PDF
Full Text)
|
|
A. M. P. Omuro, J. J. Raizer,
L. E. Abrey
A phase I trial of temozolomide and vinorelbine in
patients with recurrent brain metastases
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No. 1567
|
|
S.
Siena, G. Landonio, E. Baietta, M. Vitali, L. Crino', M. Danova, A.
Musolino, G. Gardin, P. Foa, G. Fincato
Multicenter
phase II study of temozolomide therapy for brain metastasis in patients
with malignant melanoma, breast cancer, and non-small cell lung cancer
39th ASCO Annual
Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 407
|
|
E.
Verger, M. Gil, R. Yaya, N. Vinolas, S. Villa, T. Pujol, M. V. Solano,
L. Arribas, F. Graus
Concomitant
temozolomide (TMZ) and whole brain radiotherapy (WBRT) in patients with
brain metastases (BM): Randomized multicentric phase II study
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
404
|
|
Eugenia
Verger, Miguel Gil, Ricardo Yaya, Nuria Vinolas, Salvador Villa,
Teresa Pujol, M Victoria Solano, Francesc Graus
Concomitant
temozolomide (TMZ) and radiotherapy (RT) in patients with brain
metastases: randomized multicentric phase II study, a preliminary report
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
309
|
|
|
Weller
M.
Radiochemotherapy for brain metastasis: how to define a role for
temozolomide.
Onkologie. 2007
Jul;30(7):350-1. Epub 2007 Jun 27. No abstract available.
PMID: 17596741 [PubMed - in process]
|
|
Melanoma
|
|
|
|
Schild
SE, Behl
D, Markovic
SN, Brown
PD, Sande
JR, Deming
RL, Rowland
KM Jr, Bearden
JD
Brain
Metastases From Melanoma: Is There a Role for Concurrent Temozolomide in
Addition to Whole Brain Radiation Therapy?
Am
J Clin Oncol. 2009 Dec 30. [Epub ahead of print]
Abstract |
Links |
CNO 9(2)
|
|
|
Olfactory
Neuroblastoma
|
|
|
|
|
Wolfgang Wick, Antje Wick, Wilhelm Küker,
Johannes Dichgans, Michael Weller
Intracranial
Metastatic Esthesioneuroblastoma Responsive to Temozolomide
J
Neurooncol, 70(1):73-75, Oct. 2004.
(Abstract+)
|
|
|
Oligodendroglial
Tumors
|
|
|
|
A.
A. Brandes, U. Basso, F. Vastola, L. M. Pasetto, S. Lonardi, A. Scola,
G. Ravenna, B. Coria, F. Chioffi, M. Ermani
First line chemotherapy with temozolomide (TMZ)
in recurrent or progressive oligodendroglioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
426
|
|
|
Thomas
N. Byrne
Response
of low-grade oligodendroglial tumors to temozolomide
Journal
of Neuro-Oncology, 70(3):
279-280, December 2004
|
|
|
Chinot
OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X,
Braguer D, Martin PM, Grisoli F.
Safety and efficacy of temozolomide in patients
with recurrent anaplastic oligodendrogliomas after standard radiotherapy
and chemotherapy
J Clin Oncol 2001 May 1;19(9):2449-55
|
|
H.
Kaur, L. Wood, D. Schiff, G. Barnett, M. Vogelbaum, G. Stevens, R.
Prayson, S. Staugaitis, P. Elson, D. Peereboom
Phase II multicenter study of 7/7 dosing of
temozolomide (TMZ) in patients (pts) with newly diagnosed pure and mixed
anaplastic oligodendroglioma (AO/MAO)
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
443
|
|
|
Mikkelsen
T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D,
Hasselbach L, Avedissian R, Schultz L
Temozolomide
single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma
J Neurooncol.
2009 Mar;92(1):57-63. Epub 2008 Nov 15
Abstract |
Links |
Issue
|
|
|
Netta Levin, M.D., Iris Lavon, Ph.D., R.A., Bracha
Zelikovitsh, Dana Fuchs, Bs.C., Felix Bokstein, M.D., Yakov Fellig, M.D., Tali
Siegal, M.D.
Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA
methyltransferase protein expression
Cancer, Volume 106, Issue 8 , Pages 1759 -
1765. Published Online: 15 Mar 2006
Abstract
|
|
Ozyigit
G, Onal
C, Gurkaynak
M, Soylemezoglu
F, Zorlu
F
Postoperative radiotherapy and chemotherapy in the
management of oligodendroglioma: single institutional review of 88 patients
J Neurooncol. 2005 Nov;75(2):189-93.
|
|
Martin
J van den Bent,
M J Taphoorn, A A Brandes, J Menten, R Stupp, M Frenay, C C van
der Rijt, J M Kros, A Allgeier, T Gorlia
EORTC
brain tumor group study 26971: first line chemotherapy with temozolomide in
recurrent oligodendroglial tumors; a phase II study
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract
No.
285
|
|
M
J van den Bent, O Chinot, W Boogerd, J Bravo-Marques, MJB Taphoorn, JM Kros, CDD
van de Rijt, N de Beule, B Baron, On Behalf of the EORTC Brain Tumor Group.
EORTC
Study 26972: Second Line Temozolomide Chemotherapy in Recurrent Oligodendroglial
Tumors After PCV Chemotherapy: a Phase II Study
ASCO Proceedings, 2001 Annual Meeting, Abstract No. 203
|
|
|
Pediatric
CNS
Tumors
|
|
|
|
|
Broniscer A, Gururangan S, Macdonald TJ, Goldman
S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY,
Kun LE, Boyett JM, Gajjar A; for the Pediatric Brain Tumor Consortium.
Phase I Trial of Single-Dose Temozolomide and Continuous Administration
of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor
Consortium Report
Clin
Cancer Res. 2007 Nov 15;13(22):6712-6718
Abstract
|
Links
|
|
|
Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A, Sarin
R, Kurkure P
Prospective Evaluation of Radiotherapy With Concurrent and Adjuvant
Temozolomide in Children With Newly Diagnosed Diffuse Intrinsic Pontine
Glioma
Int
J Radiat Oncol Biol Phys. 2009 Jul 31. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
K.
C. Loh, J. Willert, H. Meltzer, W. Roberts, B. Kerlin, F. Kung, M.
Levy, R. Kadota, A. Yu, M. A. Spear
Temozolomide (TMZ) and radiation (XRT) for
aggressive pediatric CNS malignancies
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8566
|
|
A
C Verschuur, J Grill, A Lelouch-Tubiana, D Couanet, C Kalifa and G
Vassal
Temozolomide
in paediatric high-grade glioma: a key for combination therapy?
British Journal of Cancer (2004) 91,
425-429.
|
|
|
Wang CH, Hsu TR, Wong TT, Chang KP
Efficacy
of temozolomide for recurrent embryonal brain tumors in children
Childs
Nerv Syst. 2008 Dec 24. [Epub ahead of print]
Abstract |
Links |
Issue
|
|
|
Pituitary
Tumors
|
|
|
|
|
Mohammed
S, Kovacs K, Mason W, Smyth H, Cusimano MD
Use of temozolomide in aggressive pituitary tumors: case report
Neurosurgery. 2009 Apr;64(4):E773-4
Abstract |
Links |
Issue
|
|
|
|
